- About Us ▼
- Products ▼
- Pipeline ▼
- Current Vacancies
- Conditions of Sale ▼
- Contact Us ▼
The EUSA Pharma Board of Directors is a group of highly experienced investment and pharmaceutical professionals with operational, strategic, regulatory, financing, R&D and HR expertise combined with extensive network of strong relationships across the industry.
Brings a wealth of experience after a 30 year career in healthcare gained at companies including Merck and Bristol Myers Squibb. Founded Zeneus in 2003 through the acquisition of Elan’s European Sales and Marketing division for $120m, and which was sold in 2005 for $360m. Founded the first EUSA Pharma Company in 2006 and which, through strategic acquisition and product development, grew by over 300% resulting in an acquisition of the business by Jazz Pharmaceuticals in 2012 for $700m.
Petri Vainio, M.D., Ph.D. has spent his entire career as an investor and board member in rapidly growing healthcare companies. He has been a lead investor in numerous successful healthcare companies in all sectors, including pharmaceuticals, biotechnology, medical devices and healthcare services. Petri has served on the board of directors of over 20 private and public healthcare companies and has helped these companies raise over $1 billion in private financings and create a combined enterprise value of over $30 billion. Petri joined Essex Woodlands as Managing Director and opened the London office in 2004 and currently serves on the Board of Directors of EW portfolio company Molecular Partners. Prior to joining Essex Woodlands, Petri spent more than 10 years as a General Partner of Sierra Ventures, one of Silicon Valley’s leading venture capital firms with over $1 billion under management. While at Sierra, he was a General Partner in five successive funds and led their healthcare investment practice. Petri holds a Doctor of Medicine and a Doctor of Philosophy degree in Biochemistry from the University of Helsinki, as well as a Masters in Business Administration degree from Stanford University.
Dr Göran Ando is Senior Advisor with EUSA Pharma’s lead shareholder, Essex Woodlands. He has over 35 years’ experience of the pharmaceutical industry, spent in a variety of senior international roles. He is currently Chairman of Novo Nordisk, the world’s leading pharmaceutical company focused on diabetes. He is also Chairman of Symphogen, and sits on the Board of Directors at Molecular Partners. Previously, he was CEO of Celltech Group plc prior to its acquisition by UCB Pharma, and was Head of R&D at Pharmacia / Pharmacia & Upjohn. Dr Ando holds a Bachelor of Arts degree from Uppsala University in Sweden and a Medical Degree from Linkoeping University (Sweden).
Brings to EUSA 50 years’ experience of the life sciences industry. In his most recent role he was a General Partner at Healthcare Ventures, one of the world’s largest venture capital firms specializing in biotechnology. In addition to his 20 years’ venture capital experience, he spent 30 years in the pharmaceutical and diagnostics industry, holding roles in general management, international operations, strategic planning, licensing, acquisitions, new product development and sales and marketing. Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International. He currently serves on the Board of The Medicines Company (NASDAQ: MDCO), and is a Director of three private biotechnology companies. He is also a Trustee and Executive Committee Member of the New York Blood Center and is a member of Lehigh University’s Business Advisory Board. He holds a BS in Finance and Economics from Lehigh University and an MBA from Pace University.
Has over 15 years of experience in both corporate finance and the pharmaceuticals industry and joined the London office of Essex Woodlands in 2007. He was promoted to Partner in 2013, and then Managing Director in June 2015. Toby led Essex’s growth equity investment in Healthcare Brands International, which was sold to Meda AB in 2011, and manages Essex Woodlands’ growth equity investments in MedAvante and Biotoscana. Prior to Essex Woodlands, Toby was Director of Business Development at Cephalon Inc, where he helped the company build its European business through a transformational acquisition and previously worked in corporate finance for Arthur Andersen and Deloitte advising on a number of growth equity and buyout transactions in the life sciences industry. Toby serves on the Board of Directors at Chroma Therapeutics and Biotoscana.
Brings extensive commercial experience gained over 20 years in the pharmaceutical industry. Most recently held position of Vice President, Head of Commercial for Europe and International Markets at Jazz Pharmaceuticals and previously held several senior commercial positions including Regional Vice President at EUSA Pharma, prior to its acquisition by Jazz, and was Director of Sales Effectiveness at the specialty oncology and critical care company Zeneus Pharma. Has held a number of management positions in sales and marketing at Merck, Sharp and Dohme (MSD), including UK National Sales Manager.
Has more than 10 years’ experience in healthcare companies after completing the ACCA qualification as a chartered accountant. Acted in both financial and commercial director positions and was part of the senior management team of EUSA Pharma prior to its acquisition by Jazz Pharmaceuticals.